Home › Funds › Two Seas Capital LP › NKTR
Two Seas Capital LP position in NKTR
NEKTAR THERAPEUTICS · Health Care
Two Seas Capital LP reported holding 3,345,978 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$202.6M, representing 2.63% of its reported portfolio and ranking #5 among its reported holdings. Two Seas Capital LP has disclosed NKTR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Two Seas Capital LP's NKTR position evolved
Two Seas Capital LP first disclosed a stake in NKTR in Q4 2025 at 745,185 shares (US$31.5M). The position peaked in Q2 2026 at 3,092,234 shares, worth US$215.9M. Across 4 filings, Two Seas Capital LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,345,978 shares valued at US$202.6M — an increase of 253,744 shares quarter over quarter.. Notable position changes include a 163% increase in Q1 2026 (shares fell 3% over the following quarter), a 58% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 745.18K | $31.51M | New |
| Q1 2026 | 1.96M | $140.96M | Add |
| Q2 2026 | 3.09M | $215.87M | Add |
| Q3 2026 | 3.35M | $202.58M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 70 other funds we track also report a position in NKTR — the largest reported positions include BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M), Prosight Management, LP (US$56.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- Prosight Management, LP 810.00K sh · $56.55M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K sh · $50.54M · Q2 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K sh · $32.93M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K sh · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- 22NW, LP 281.12K sh · $19.62M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K sh · $17.05M · Q2 2026
- Creek Drive Management Group LLC 243.00K sh · $16.96M · Q2 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $16.75M · Q2 2026
More on Two Seas Capital LP
FAQ
How long has Two Seas Capital LP held NKTR?
Two Seas Capital LP has disclosed NKTR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Two Seas Capital LP's current position in NKTR?
As of Q3 2026, Two Seas Capital LP holds 3.35M shares of NKTR (NEKTAR THERAPEUTICS), valued at $202.58M, representing 2.63% of its reported portfolio and ranking #5.
Has Two Seas Capital LP been buying or selling NKTR?
In the latest 13F filing (Q3 2026), Two Seas Capital LP increased its position in NKTR. The position peaked in Q2 2026 at 3.09M shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include BVF INC/IL, Vestal Point Capital, LP, Prosight Management, LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.